Advanced Oncotherapy PLC Two-Year Collaborative Research Study (5681V)
04 Dicembre 2019 - 8:00AM
UK Regulatory
TIDMAVO
RNS Number : 5681V
Advanced Oncotherapy PLC
04 December 2019
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). With the
publication of this announcement via a Regulatory Information
Service, this inside information is now considered to be in the
public domain.
4 December 2019
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Advanced Oncotherapy plc (AIM: AVO) announces a two-year
collaborative research study.
Under the agreement, Advanced Oncotherapy plc (AIM:AVO) and
Cleveland Clinic, a large academic medical centre in Cleveland,
Ohio, USA will commence a two-year study to evaluate the target
conformity of proton minibeams in comparison with X-ray
stereotactic body radiation therapy ("SBRT") and stereotactic
radiosurgery ("SRS").
Further explanatory details on the research collaboration, SBRT
and SRS are set out below.
- ENDS -
Advanced Oncotherapy plc www.avoplc.com
Dr. Michael Sinclair, Executive Tel: +44 (0) 20 3617 8728
Chairman
Nicolas Serandour, CEO
Allenby Capital Limited (Nomad
& Broker)
Nick Athanas / Liz Kirchner / Tel: +44 (0) 20 7601 6100
Nicholas Chambers
FTI Consulting (Financial PR & advancedoncotherapy@fticonsulting.com
IR)
Simon Conway / Rob Winder Tel: +44 (0) 20 3727 1000
Notes for Editors
About the research collaboration
Innovation in radiotherapy is focused on increasing the efficacy
of treatment and improving quality of life for patients through a
reduction of side effects or increased long-term survival. The most
challenging goal of radiotherapy is ensuring that only the
cancerous tissue is targeted, avoiding the irradiation of healthy
tissue. The use of a smaller beam means greater accuracy in
targeting the desired tissue, which is essential when treating
tumours near critical organs, particularly for the edge of the
tumours.
Focus within proton therapy is on initiatives to generate
smaller and more accurate beams. Advanced Oncotherapy's LIGHT has
been designed to generate a much smaller beam, a minibeam, than is
possible with current proton therapy technology.
Proton mini beam radiation therapy ("pMBRT")
Proton minibeam radiation therapy is an approach to radiation
therapy that allies the inherent physical advantages of protons
with the normal tissue preservation when the tumour is irradiated
with sub-millimetric proton beams, i.e., below the current standard
size of proton beams.
X-ray stereotactic body radiation therapy ("SBRT") and X-ray
stereotactic radiosurgery ("SRS")
Stereotactic radiosurgery (SRS) is a non-surgical radiation
therapy used to treat functional abnormalities and small tumours of
the brain. It can deliver precisely-targeted radiation in fewer
high-dose treatments than traditional therapy. When SRS is used to
treat body tumours, it is called stereotactic body radiotherapy
(SBRT).
About Advanced Oncotherapy Plc www.avoplc.com
Advanced Oncotherapy, a UK headquartered company with offices in
London, Geneva, The Netherlands and in the USA, is a provider of
particle therapy with protons that harnesses the best in modern
technology. Advanced Oncotherapy's team "ADAM," based in Geneva,
focuses on the development of a proprietary proton accelerator
called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's
compact configuration delivers proton beams in a way that
facilitates greater precision and electronic control.
Advanced Oncotherapy will offer healthcare providers affordable
systems that will enable them to treat cancer with innovative
technology as well as expected lower treatment-related side
effects.
Advanced Oncotherapy continually monitors the market for any
emerging improvements in delivering proton therapy and actively
seeks working relationships with providers of these innovative
technologies. Through these relationships, the Company will remain
the prime provider of an innovative and cost-effective system for
particle therapy with protons.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGRMMMGZLFNGLZM
(END) Dow Jones Newswires
December 04, 2019 02:00 ET (07:00 GMT)
Grafico Azioni Advanced Oncotherapy (LSE:AVO)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Advanced Oncotherapy (LSE:AVO)
Storico
Da Apr 2023 a Apr 2024